Medico Remedies Ltd. · NSE:MEDICO
Medico Remedies — Q2 FY2024 Earnings Presentation
22 slides from Medico Remedies's earnings presentation, Jan 11, 2024
Slide 1: Exchange filing cover letter
Date: 11th January, 2024 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai-400051 Scrip Code: 540937 Symbol: MEDICO Dear Sir/Madam, Sub: Investor Presentation for Q2 FY 202
Slide 2: Medico Remedies Limited Investor Presentation December 2023
a4 MEDICO REMEDIES LIMITED EXCELLENCE IN HEALTHCARE EVERYDAY Investor Presentation December 2023
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Medico Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securi
Slide 4: About the Company
About the Company Established in 1994, Medico is a_ formulation > manufacturing company with focus on anti-infective, Beta- Lactums, Cephalosporin, Antimalarial, Antiretroviral, Anti- ulcer drugs and antacids, Vitamins, Haematinics and other supplements. Manufacturing and Marketing capabilities in o
Slide 5: Our Vision and Values
Our Vision and Values Values Vision * Customer satisfaction above all * Quality medicine at affordable cost + Healthy working environment for all * Continuous upgradation and improvement Driven by the passion to create a healthier and happier tomorrow, Medico Remedies is taking giant strides in esta
Slide 6: Our Global Presence
Our Global Presence = Dominican Republic = Turkmenistan = Honduras = Philippines = Nigeria = Hong Kong = Vietnam = Cameroon ™ Kenya ™ Medagaskar = Myanmar © Liberia = Srilanka = Somelia = Bhuton ® Sierra Leonne = Panama = Armenia ™ Cuba ™ Peru ~ = Ugando = Jamaico = Iraq = Gabon = Mali = Burundi = F
Slide 7: Our Market
US$ 1.6 Trillion Global Market : US$ 1.6 Trillion India Pharmaceutical Market : US$ 50 Billion India Pharmaceutical Market is likely to be touched US$130 billion by 2030.
Slide 8: Our Milestones
Our Milestones 1994 1999-02 |__| 2016 |__| 2017 Incorporated as Medico Set up Manufacturing Renewed WHO-GMP Renewed ISO- Remedies Private Ltd Facility for Beta-Lactam Certification for 9001:2015 Certification and Formulation manufacturing facility for manufacturing Purchased corporate facility and C
Slide 9: Our Milestones
Our Milestones 2018 2019 |__| 2021 |__| 2021-22 Listed on BSE limited — Setting up new facility Crossed the revenue of Acquired plot for SME Platform at Palghar Rs. 100 Crores in the storage and production Financial Year 2020- facility at Palghar 2021
Slide 10: Our Product Portfolio
Our Product Portfolio Anti Biotic & Anti Infective Beta-lactams- Penicillins And Cephalosporins Antifungals Vitamins & Supplements oxycycline Capsules Cefpomed 200mg Fluconazole Capsules Ommed-20 Capsules |Zenof-400 (Ofloxacin Tablets 400mg) Ampicillin 500mg Nystatin Vaginal Tablets Lansoprazole Cap
Slide 11: Our Product Portfolio
aeaO 3 tie i i Cardiovascular Bisoprolol Fumarate Antipyretic, Analgesic. NSAI Antidepressant: Antacid, Anti-Ulcer Drugs GX gentile 4/0) ae Jamindine (Cimetidine) Paramed-500 Folic Acid Tablets Tablets BP 200 mg |Artemether and Lumefantrine itamin. Caprilcare (Captopril) Tablets, Tablets Upfenac Tab
Slide 12: Our Product Portfolio
Our Product Portfolio Syrups Syrups Miscellaneous Antimalarials ° 4 - {2 Erythromycin Oral a a 8 Suspension 125mq/5ml Tos Syrup Carbin 5 Tablets Quinine Sulphate Tablets \3 i \\o Amoxicillin Oral Suspension Glucosamine Sulfate |Artemether and Lumefantrine| H] Ibuprofen Syrup 100mg/5ml | H 250mg/5ml
Slide 13: Our Board of Directors
Our Board of Currently, Mr. Haresh Mehta aged 62 is the Chairman & Chief Financial Officer of our Company. He is a founding member of our Company. He now looks after the Financial and Legal departments of our Company. He holds Bachelor’s Degree of Pharmacy from the University of Bombay and a diploma
Slide 14: Our Board of Directors
Our Board of Presently, Mr. Deepesh Shah is Additional Non-Executive Independent Director of our Company. He has obtained his Bachelors of commerce degree from the University of Mumbai in the year 1999. He has Directors worked at senior designations at various big companies in Media & Communication
Slide 15: Our Certification
a(n ene ® Government Recognized Pharmacy and Poisons Bott Star Export House
Slide 16: Q2FY24 Financial Performance
Q2FY24 Financial Performance Sequentially Revenue Grew by 35% EBITDA increased by 25% QoQ ₹ 42.4 cr ₹ 40.5 cr ₹ 3.1 cr ₹ 3.1 cr YoY 5% ₹ 31.5 cr ₹ 2.5 cr QoQ 35% Q2FY23 Q1FY24 Q2FY24 Q2FY23 Q1FY24 Q2FY24 Net Profit Up by 84% QoQ ₹ 2.9 cr ₹ 2.4 cr ₹ 1.3 cr Q2FY23 Q1FY24 Q2FY24
Slide 17: Quarterly Snapshot
Quarterly Snapshot INR Cr Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Sales 33.1 40.5 38.9 28.0 31.5 42.4 Expenses 33.3 37.3 35.5 24.8 29.0 39.3 EBITDA -0.2 3.1 3.4 3.2 2.5 3.1 Other 1.6 1.6 0.9 0.0 0.3 1.0 Income Depreciation 0.6 0.7 0.7 0.7 0.7 0.7 Interest 0.2 0.2 0.2 0.2 0.2 0.2 Profit before 0.7
Slide 18: Key Growth Drivers
Key Growth Drivers >» Revenue growth guidance : 15-20% > In H1FY24, started business in Somalia and won few big tender in Burundi. Sri Lanka business picked up very well. Planning to add 2-3 countries every year. > Key product in pipeline are Ointment and Cephalosporin. Many Products are under regis
Slide 19: 5 Year Financial Performance
5 Year Financial Performance Revenue CAGR Growth 18% over FY18-FY23 Profitability Margin Improvement Continues... Healthy Return Ratio EBITDAM PAT MARGIN RoE ROCE ₹ 140 cr ₹ 122 cr ₹ 121 cr 7% 21% 6% ₹ 98 cr 6% ₹ 89 cr 15% 4% 5% 17% ₹ 61 cr 3% 10% 3% 4% 9% 13% 8% 8% 8% 2% 2% 2% 2% 6% 5% 5% FY18 FY19
Slide 20: Income Statement
Income Statement INR cr FY18 FY19 FY20 FY21 FY22 FY23 Sales 61 98 89 122 121 140 Expenses 58 95 86 117 114 131 Operating Profit 3 3 3 5 7 10 Other Income 1 2 2 1 2 4 Depreciation 1 2 2 2 2 3 Interest 2 1 1 1 1 1 Profit before tax 2 2 2 4 6 10 Tax 1 1 1 1 2 3 Net profit 1 2 2 3 5 7 EPS (Rs) 0.15 0.19
Slide 21: Balancesheet
Balancesheet Particulars (Inr cr) FY18 FY19 FY20 FY21 FY22 FY23 Share Capital 4 4 4 4 17 17 Reserves and Surplus 23 24 26 28 21 27 Total Equity 27 28 30 33 37 44 Long Term Borrowings 2 2 5 5 1 0 Deferred Tax Liabilities (Net) 0 0 0 0 0 0 Other Long Term Borrowings 0 0 0 0 0 1 Long Term Provisions 0
Slide 22: Connect with us.
Connect with us. Medico Remedies Limited Q 1105/1106, Hubtown Solaris, N.S.Phadke Marg, opp.teligali, Andheri East , Mumbai-400069. & +91-22-26701055 /+91-22-26701066/+91- ———— 22- 68943803 info @ medico.com P—— 4